SwePub
Sök i LIBRIS databas

  Utökad sökning

(WFRF:(Strand Sven Erik))
 

Sökning: (WFRF:(Strand Sven Erik)) > (2020-2024) > Humanization, radio...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005287naa a2200469 4500
001oai:lup.lub.lu.se:3fd8f991-c120-47cd-b263-e6b2f9bda772
003SwePub
008220127s2021 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:148490149
024a https://lup.lub.lu.se/record/3fd8f991-c120-47cd-b263-e6b2f9bda7722 URI
024a https://doi.org/10.3390/ph141212512 DOI
024a http://kipublications.ki.se/Default.aspx?queryparsed=id:1484901492 URI
040 a (SwePub)lud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
100a Strand, Joannau Lund University,Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Strålterapi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Radiation therapy,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)jo5371st
2451 0a Humanization, radiolabeling and biodistribution studies of an igg1-type antibody targeting uncomplexed psa for theranostic applications
264 c 2021-12-01
264 1b MDPI AG,c 2021
520 a Metastatic castration-resistant prostate cancer is today incurable. Conventional imaging methods have limited detection, affecting their ability to give an accurate outcome prognosis, and current therapies for metastatic prostate cancer are insufficient. This inevitably leads to patients relapsing with castration-resistant prostate cancer. Targeting prostate-specific antigens whose expression is closely linked to the activity in the androgen receptor pathway, and thus the pathogenesis of prostate cancer, is a possible way to increase specificity and reduce off-target effects. We have humanized and evaluated radioimmunoconjugates of a previously murine antibody, m5A10, targeting PSA intended for theranostics of hormone-refractory prostate cancer. The humanized antibody h5A10 was expressed in mammalian HEK293 cells transfected with the nucleotide sequences for the heavy and light chains of the antibody. Cell culture medium was filtered and purified by Protein G chromatography, and the buffer was changed to PBS pH 7.4 by dialysis. Murine and humanized 5A10 were conjugated with p-SCN-Bn-CHX-A”-DTPA. Surface plasmon resonance was used to characterize the binding to PSA of the immunoconjugates. Immunoconjugates were labeled with either indium-111 or lutetium-177. Biodistribution studies of murine and humanized 5A10 were performed in mice with LNCaP xenografts. 5A10 was successfully humanized, and in vivo targeting showed specific binding in xenografts. The results thus give an excellent platform for further theranostic development of humanized 5A10 for clinical applications.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653 a 5A10
653 a FPSA
653 a Humanization
653 a Imaging
653 a Prostate cancer
653 a Theranostics
700a Sjöström, Kjellu Innovagen AB4 aut
700a Lamminmaki, Urpo J.u University of Turku4 aut
700a Timmermand, Oskar Vilhelmssonu Lund University,Lunds universitet,Forskningsgruppen för Systemisk strålterapi,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Strålterapi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Systemic Radiation Therapy Group,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Radiation therapy,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)immu-orv
700a Strand, Sven Eriku Lund University,Lunds universitet,Medicinsk strålningsfysik, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Forskningsgruppen för Systemisk strålterapi,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Strålterapi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medical Radiation Physics, Lund,Section V,Department of Clinical Sciences, Lund,Faculty of Medicine,Systemic Radiation Therapy Group,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Radiation therapy,Section I,Department of Clinical Sciences, Lund4 aut0 (Swepub:lu)rafy-ses
700a Tran, Thuy A.u Karolinska Institutet,Karolinska Institute,Karolinska University Hospital4 aut0 (Swepub:lu)med-tht
710a LUCC: Lunds universitets cancercentrumb Övriga starka forskningsmiljöer4 org
773t Pharmaceuticalsd : MDPI AGg 14:12q 14:12x 1424-8247
856u http://dx.doi.org/10.3390/ph14121251x freey FULLTEXT
856u https://www.mdpi.com/1424-8247/14/12/1251/pdf
8564 8u https://lup.lub.lu.se/record/3fd8f991-c120-47cd-b263-e6b2f9bda772
8564 8u https://doi.org/10.3390/ph14121251
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:148490149

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy